173 related articles for article (PubMed ID: 30073607)
21. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions.
Torralba KD; De Jesus E; Rachabattula S
Int J Rheum Dis; 2012 Dec; 15(6):499-506. PubMed ID: 23253231
[TBL] [Abstract][Full Text] [Related]
22. Accuracy of the HumaSens
Fabre S; Clerson P; Launay JM; Gautier JF; Vidal-Trecan T; Riveline JP; Platt A; Abrahamsson A; Miner JN; Hughes G; Richette P; Bardin T
Arthritis Res Ther; 2018 May; 20(1):78. PubMed ID: 29720236
[TBL] [Abstract][Full Text] [Related]
23. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout).
Becker MA
Rheum Dis Clin North Am; 1988 Aug; 14(2):377-94. PubMed ID: 3051156
[TBL] [Abstract][Full Text] [Related]
24. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
25. Estimation of serum uric acid in cases of hyperuricaemia and gout.
Pokharel K; Yadav BK; Jha B; Parajuli K; Pokharel RK
JNMA J Nepal Med Assoc; 2011; 51(181):15-20. PubMed ID: 22335090
[TBL] [Abstract][Full Text] [Related]
26. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
27. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Wortmann RL; Macdonald PA; Hunt B; Jackson RL
Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
[TBL] [Abstract][Full Text] [Related]
28. The kidney in hyperuricemia and gout.
Mount DB
Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):216-23. PubMed ID: 23318701
[TBL] [Abstract][Full Text] [Related]
29. Quantitative proteomics by iTRAQ-PRM based reveals the new characterization for gout.
Chen G; Cheng J; Yu H; Huang X; Bao H; Qin L; Wang L; Song Y; Liu X; Peng A
Proteome Sci; 2021 Oct; 19(1):12. PubMed ID: 34635120
[TBL] [Abstract][Full Text] [Related]
30. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study.
Dalbeth N; House ME; Aati O; Tan P; Franklin C; Horne A; Gamble GD; Stamp LK; Doyle AJ; McQueen FM
Ann Rheum Dis; 2015 May; 74(5):908-11. PubMed ID: 25637002
[TBL] [Abstract][Full Text] [Related]
31. An association of smoking with serum urate and gout: A health paradox.
Fanning N; Merriman TR; Dalbeth N; Stamp LK
Semin Arthritis Rheum; 2018 Jun; 47(6):825-842. PubMed ID: 29398126
[TBL] [Abstract][Full Text] [Related]
32. Urate testing in gout: why, when and how.
Dalbeth N; Winnard D; Gow PJ; Boswell DR; Te Karu L; Lindsay K; Arroll B; Stamp LK
N Z Med J; 2015 Aug; 128(1420):65-8. PubMed ID: 26367514
[TBL] [Abstract][Full Text] [Related]
33. Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase.
Drabkin M; Yogev Y; Zeller L; Zarivach R; Zalk R; Halperin D; Wormser O; Gurevich E; Landau D; Kadir R; Perez Y; Birk OS
J Clin Invest; 2019 Dec; 129(12):5163-5168. PubMed ID: 31638601
[TBL] [Abstract][Full Text] [Related]
34. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
35. (1)H NMR and MS based metabolomics study of the therapeutic effect of Cortex Fraxini on hyperuricemic rats.
Wang Y; Zhao M; Xin Y; Liu J; Wang M; Zhao C
J Ethnopharmacol; 2016 Jun; 185():272-81. PubMed ID: 27001626
[TBL] [Abstract][Full Text] [Related]
36. [Hyperuricemia and Gout].
Delbarba E; Terlizzi V; Dallera N; Izzi C; Scolari F
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960024
[TBL] [Abstract][Full Text] [Related]
37. Safety of urate-lowering therapies: managing the risks to gain the benefits.
Keenan RT
Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
[TBL] [Abstract][Full Text] [Related]
38. Gout and hyperuricemia.
Harris MD; Siegel LB; Alloway JA
Am Fam Physician; 1999 Feb; 59(4):925-34. PubMed ID: 10068714
[TBL] [Abstract][Full Text] [Related]
39. Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
Meng ZQ; Tang ZH; Yan YX; Guo CR; Cao L; Ding G; Huang WZ; Wang ZZ; Wang KD; Xiao W; Yang ZL
Am J Chin Med; 2014; 42(6):1471-83. PubMed ID: 25384446
[TBL] [Abstract][Full Text] [Related]
40. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
